Pharma Two B
Innovative Combinations of Previously Approved Drugs
Company Overview
Snapshot
Founded in March 2007 by Dr. Nurit Livnah, Pharma Two B operates with 1–10 employees. The company has raised $46.11 million across 4 funding rounds from 8 investors. In September 2024, Pharma Two B announced the filing of a registration statement with the SEC for a proposed merger with Hepion Pharmaceuticals, aiming to become a publicly traded company on Nasdaq.
Business overview
Pharma Two B is a clinical-stage pharmaceutical company focused on developing differentiated and value-added products by combining previously approved drugs. The company's core approach aims to enhance efficacy, safety, and delivery profiles, thereby increasing clinical value and accelerating regulatory approval timelines. Pharma Two B primarily serves the pharmaceutical and healthcare markets, with a lead product candidate, P2B001, targeting early-stage Parkinson's disease.
Strategic signal
In March 2025, news emerged that Pharma Two B had ceased operations due to a failure in drug production. This development signals a critical setback for the company and its investors, indicating a significant challenge in its clinical development and commercialization strategy, despite previous positive clinical trial results and merger plans.
Log in to access full profile ›Company Intelligence Q&A
- What is the current operational status of Pharma Two B?
- Pharma Two B ceased to operate in July 2025, following a failure in drug production that was reported in March 2025.
- What was the company's most recent strategic corporate development?
- In September 2024, Pharma Two B and Hepion Pharmaceuticals, Inc. announced the filing of a registration statement with the SEC for a proposed merger, which aimed for Pharma Two B to become a publicly traded company on Nasdaq.
- What was the valuation of the proposed merger with Hepion Pharmaceuticals?
- The proposed merger with Hepion Pharmaceuticals, announced in July 2024, had a pro-forma equity value of around $58.5 million.
- What was the outcome of the Phase 3 trial for P2B001?
- In April 2022, Pharma Two B presented positive efficacy and safety data from its Phase 3 trial of P2B001 for early Parkinson's disease at the American Academy of Neurology Annual Meeting, indicating significant improvement in motor symptoms and daily function.
- Did Pharma Two B secure any licensing agreements for P2B001?
- In November 2021, Pharma Two B announced a licensing and investment agreement with.